Adma Biologics (ADMA) Q2 Revenue Up 14%

Adma Biologics (ADMA -2.21%), a plasma-derived biologics manufacturer focused on immunotherapies, released its earnings for Q2 2025 on August 6, 2025. The quarter showed continued revenue growth, with GAAP total revenue of $122.0 million, with total revenue (GAAP) reaching $122.0 million, edging out analyst consensus on GAAP total revenue. Earnings per share (EPS) were $0.14 (GAAP), while Adjusted net income and adjusted EBITDA also advanced. Gross margin (GAAP) improved to 55.1%, up from 53.6% in Q2 2024. ...